Skip to main content

CSL Value Stock - Dividend - Research Selection

CSL Ltd

ISIN: AU000000CSL8, WKN: 890952

Market price date: 11.09.2020
Market price: 103,39 USD




CSL Ltd Fundamental data and company key figures of the share

Annual reports in USD
Key figures 22-08-2020
Cash flow
Net operating cash flow 2.488.300.000
Capital Expenditures -1.206.800.000
Free cash flow 1.281.500.032
Balance sheet
Total Equity 6.527.400.000
Liabilities & Shareholders equity 15.464.600.000
Income statement
Net income 2.102.500.000
Eps (diluted) 2,308
Diluted shares outstanding 911.159.000
Net sales/revenue 9.150.800.000

Fundamental ratios calculated on: 11-09-2020

Ratios
Key figures 11-09-2020
Cash flow
P/C 37,82
   
P/FC 73,44
Balance sheet
ROI13,60
ROE42,21
Income statement
P/E44,76
Div. Yield0,89%
P/B14,42
P/S10,29


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolCSLLY
Market Capitalization94.204.731.392,00 USD
CountryAustralia
IndicesASX 200
SectorsPharma
Raw Data SourceIFRS in Millionen USD
Stock Split
Internetwww.csl.com.au


Description of the company

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza vaccines. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.csl.com.au